RCUS

2021년 6월 18일

This BioScience company has many products in the testing phases through to the FDA approvals. The stock has also missed earnings multiple times in the past and that is the majority reason why it is currently failing. keep a watch on this to see if it hits new lows and can be a great buy if one of the FDA approvals approaches and the company could see significant increases in revenue and earnings causing the price to go up